Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease

被引：15
作者：
Lee, Han Ah [1 ]
Kim, Hwi Young [1 ]
机构：
[1] Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul 07985, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 11期
基金：
新加坡国家研究基金会;
关键词：
nonalcoholic steatohepatitis; diabetes; liraglutide; semaglutide; tirzepatide; HEPATIC STEATOSIS; GLP-1; ANALOG; VITAMIN-E; DUAL GIP; LIRAGLUTIDE; METFORMIN; OBESITY; TRIAL; STEATOHEPATITIS; ADIPONECTIN;
D O I：
10.3390/ijms24119324
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Nonalcoholic fatty liver disease (NAFLD) can lead to liver fibrosis and cirrhosis. Recently, glucagon-like peptide 1 receptor agonists (GLP-1RAs), a class of drugs used to treat type 2 diabetes and obesity, have shown therapeutic effects against NAFLD. In addition to reducing blood glucose levels and body weight, GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD. Additionally, GLP-1RAs have a good safety profile with minor side effects, such as nausea and vomiting. Overall, GLP-1RAs show promise as a potential treatment for NAFLD, and further studies are required to determine their long-term safety and efficacy.
引用
收藏
页数：17
相关论文
共 66 条
  • [11] 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Buse, John B.
    Wexler, Deborah J.
    Tsapas, Apostolos
    Rossing, Peter
    Mingrone, Geltrude
    Mathieu, Chantal
    D'Alessio, David A.
    Davies, Melanie J.
    [J]. DIABETES CARE, 2020, 43 (02) : 487 - 493
  • [12] Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
    Capehorn, M. S.
    Catarig, A-M
    Furberg, J. K.
    Janez, A.
    Price, H. C.
    Tadayon, S.
    Verges, B.
    Marre, M.
    [J]. DIABETES & METABOLISM, 2020, 46 (02) : 100 - 109
  • [13] Cariou B, 2015, DIABETES METAB, V41, pS28, DOI 10.1016/S1262-3636(16)30006-4
  • [14] Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression
    Chung, Le Thi Kim
    Hosaka, Toshio
    Yoshida, Masaki
    Harada, Nagakatsu
    Sakaue, Hiroshi
    Sakai, Tohru
    Nakaya, Yutaka
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 390 (03) : 613 - 618
  • [15] Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
    Clemmensen, Christoffer
    Finan, Brian
    Mueller, Timo D.
    DiMarchi, Richard D.
    Tschoep, Matthias H.
    Hofmann, Susanna M.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (02) : 90 - 104
  • [16] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
    Coskun, Tamer
    Sloop, Kyle W.
    Loghin, Corina
    Alsina-Fernandez, Jorge
    Urva, Shweta
    Bokvist, Krister B.
    Cui, Xuewei
    Briere, Daniel A.
    Cabrera, Over
    Roell, William C.
    Kuchibhotla, Uma
    Moyers, Julie S.
    Benson, Charles T.
    Gimeno, Ruth E.
    D'Alessio, David A.
    Haupt, Axel
    [J]. MOLECULAR METABOLISM, 2018, 18 : 3 - 14
  • [17] Global burden of liver disease: 2023 update
    Devarbhavi, Harshad
    Asrani, Sumeet K.
    Arab, Juan Pablo
    Nartey, Yvonne Ayerki
    Pose, Elisa
    Kamath, Patrick S.
    [J]. JOURNAL OF HEPATOLOGY, 2023, 79 (02) : 516 - 537
  • [18] Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
    Ding, XK
    Saxena, NK
    Lin, SB
    Gupta, N
    Anania, FA
    [J]. HEPATOLOGY, 2006, 43 (01) : 173 - 181
  • [19] Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
    Drucker, Daniel J.
    [J]. CELL METABOLISM, 2018, 27 (04) : 740 - 756
  • [20] Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
    Dutour, A.
    Abdesselam, I.
    Ancel, P.
    Kober, F.
    Mrad, G.
    Darmon, P.
    Ronsin, O.
    Pradel, V.
    Lesavre, N.
    Martin, J. C.
    Jacquier, A.
    Lefur, Y.
    Bernard, M.
    Gaborit, B.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (09) : 882 - 891
1234567